This report contains detailed information about the company's business finances and management.
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 94.05 | 1.36 1.47% | 2.81% | 7,230,331 | 6.4M |
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, November 7, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Elan Corporation, plc (ADR) (NYSE: ELN), Tenet Healthcare Corp. (NYSE: THC), Opko Health Inc. (NYSE: OPK), and Keryx Biopharmaceuticals (NASDAQ: KERX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
NEW BRUNSWICK, N.J., Nov. 5, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 2013 Health Care Conference on Tuesday, Nov. 12(th) , at The Phoenician, 6000 East Camelback Road, Scottsdale, AZ. Dominic J. Caruso, Vice President, Finance & Chief Financial Officer, will represent the company in a session scheduled at 10:00 a.m. (Mountain Standard Time).
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--November 04, 2013-- Today, Nolan Auerbach & White announces the conclusion of its client's 8-year-long civil False Claims Act case against Johnson & Johnson and its subsidiary Scios, Inc. The qui tam case was brought in July 2005 by Joe Strom, a former Scios Area Manager. Both Defendants will pay $184 million to resolve civil allegations that they unlawfully promoted their cardiac drug Natrecor for unapproved uses. In addition, in 2011, Scios agreed to pay an $85 million criminal fine and to plead guilty to a misdemeanor charge of introducing misbranded Natrecor into interstate commerce. This settlement was announced today by the United States as part of a $2.2 billion global settlement between the government and Johnson & Johnson.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products in virtually all countries throughout the world. In March 2013, Johnson & Johnson's Cordis Corporation announced the acquisition Of Flexible Stenting Solutions, Inc. In June 2013, Johnson & Johnson announced the opening of the Johnson & Johnson Innovation center in Boston. In August 2013, Johnson & Johnson announced it has completed its acquisition of Aragon Pharmaceuticals, Inc., a pharmaceutical discovery and development company focused on drugs to treat hormonally driven cancers.
| Bid/Size | Ask/Size |
|---|---|
| -- / -- | -- / -- |
| Price Open | Previous Close |
|---|---|
| 92.63 | 92.69 |
| Day High | Day Low |
|---|---|
| 94.10 | 92.56 |
| 52wk High/Date | 52wk Low/Date |
|---|---|
| 94.42 / 7/31/2013 | 68.51 / 11/16/2012 |
| % off 52wk High | % off 52wk Low |
|---|---|
| -0.39% | 37.28% |
| Beta (5 Yr) | Market Capitalization |
|---|---|
| 0.6 | 265.4B |
| Shares Outstanding | Volatility Avg |
|---|---|
| 2.8B | 12.04 |
| EPS(TTM) | P/E Ratio |
|---|---|
| 4.48 | 21.0 |
| Dividend Announcement | Dividend Yield |
|---|---|
| 10/17/2013 | 2.81% |
| Ex-Date | Date of Record |
|---|---|
| 11/22/2013 | 11/26/2013 |
| Payable | Payable Date |
|---|---|
| 0.66 - QRTR | 12/10/2013 |
| Peers | |
|---|---|
JNJ Johnson & Johnson | 34.17% |
General Electric Company | 28.87% |
The Procter & Gamble Company | 21.53% |
Pfizer Inc. | 24.88% |
JNJ Johnson & Johnson | 2.81% |
General Electric Company | 2.81% |
The Procter & Gamble Company | 2.92% |
Pfizer Inc. | 3.07% |
JNJ Johnson & Johnson | 1.47% |
General Electric Company | 1.69% |
The Procter & Gamble Company | 0.23% |
Pfizer Inc. | 1.33% |